reptides › growth hormone › ghrp-6

ghrp-6

older sibling of GHRP-2. even more appetite, same cortisol issues. ipamorelin made it obsolete.

tier D · growth hormone · Bowers '84 first ghrelin mimetic

verdict

older sibling of GHRP-2. even more appetite, same cortisol issues. ipamorelin made it obsolete.

if you're asking about GHRP-6 for the appetite effect — this is the lane it still occupies. the hunger spike kicks in 20-40 minutes after injection and is intrinsic to ghrelin-receptor pharmacology, not a dosing artifact. in the 2000s, this was the selling point for bodybuilders eating at surplus during bulks. cortisol, prolactin, and water retention come along with the GH pulse (Frieboes 1999, Penalva 1993).

if you're asking GHRP-6 vs GHRP-2 vs ipamorelin — GHRP-6 has the most pronounced hunger of the three. GHRP-2 has somewhat less. ipamorelin produces a cleaner GH signal with no cortisol or prolactin baggage. the use case that survives for GHRP-6 is specifically appetite stimulation, not a better secretagogue profile.

if you came in for the GH pulse itself — the GH release works. the appetite stimulation works. both come bundled with cortisol elevation, prolactin elevation, and the broader stress-axis effects. modern GH-axis protocols pair a GHRH analog with ipamorelin instead. the 2024 intranasal mouse work on central ghrelin signaling keeps the compound biologically interesting, not clinically rehabilitated.

based on published evidence and disclosed clinical practice. not medical advice.

why D-tier

D-tier for the same reason as GHRP-2: a cleaner alternative (ipamorelin) exists at the same price and availability. Not F-tier because GHRP-6 does what it claims, pulsatile GH release, real appetite stimulation. The tier is about obsolescence, not failure. If ipamorelin didn't exist, this compound would be B-tier with specific cautions. With ipamorelin on the market and costing the same, the surviving niche is appetite stimulation, not a better GH-secretagogue profile.

the core tension

GHRP-6 is the compound GHRP-2 replaced, which was then itself replaced by ipamorelin. Same GHSR agonism, same pulsatile GH release, same mechanism. It does work, users get the GH pulse they're after. The distinguishing feature is the appetite effect: GHRP-6 produces substantial hunger, more pronounced than GHRP-2 and vastly more than ipamorelin. In the 2000s, bodybuilders during bulking phases used this specifically for the appetite stimulation. That use case exists. It's also rendered almost completely obsolete by ipamorelin (for the GH release) plus any appetite stimulant of choice (for the hunger), two compounds doing each job cleanly beats one compound doing both jobs messily.

what it is

ghrp-6 is a synthetic hexapeptide and the original GHRP-class ghrelin receptor agonist, designed by Cyril Bowers and Frank Momany at Tulane University in 1984. It binds GHSR in the pituitary and hypothalamus, triggers pulsatile growth hormone release, and produces the strongest appetite stimulation of the GHRP family via NPY-Y1 circuits (a rodent finding that translated unevenly to human appetite signal).

what it does

ghrp-6 produces a pulsatile GH release similar in mechanism to ghrp-2 but with even more pronounced hunger. The appetite effect kicks in 20-40 minutes after injection and is intrinsic to ghrelin-receptor pharmacology, not a dosing artifact. Cortisol, prolactin, and water retention come along with the GH pulse.

origin

developed in the 1980s as one of the first synthetic ghrelin mimetics. Investigated clinically for GH deficiency and short stature without achieving approval. Dominant in GH-secretagogue community discussion 2000-2010, displaced first by ghrp-2, then by ipamorelin from 2015 onward.

why researchers are interested

in the 2000s, the appetite-stimulating side effect was the selling point for bodybuilders trying to eat in surplus during bulks. Pricing is among the cheapest in the GH-secretagogue space. The mechanism is real and the GH pulse is reliable. The 2024 intranasal mouse study on central ghrelin signaling keeps the compound biologically interesting, if not clinically rehabilitated.

does it work

the GH release works. So does the appetite stimulation. Both come bundled with cortisol elevation, prolactin elevation, and the broader stress-axis effects documented by Frieboes 1999 and Penalva 1993. Ipamorelin produces a cleaner GH signal. The use case that survives is appetite stimulation, not a better secretagogue profile.

claims vs the data

  • stimulates pulsatile GH release — supported — Core pharmacology, confirmed across clinical and community use. The compound works.
  • produces substantial appetite stimulation — supported — The most pronounced appetite effect of the common GHRPs, more than GHRP-2, far more than ipamorelin. This is pharmacologically expected (more robust GHSR agonism).
  • elevates cortisol and prolactin — supported — Documented in clinical work. The same issue that drove the community migration away from GHRP-2 applies equally to GHRP-6.
  • better for bulking than ipamorelin due to appetite effect — partially true — The appetite effect is real and some users like it for high-calorie-intake phases. Whether this is a better strategy than just eating more food without the cortisol/prolactin burden is not obviously true.
  • equivalent or superior to ipamorelin for GH release — contradicted — Same target, worse side-effect profile. The only thing GHRP-6 does better is stimulate hunger, which is a side effect most users don't want.

key facts

  • molecular formula: C46H56N12O6
  • molecular weight: 873.01 Da
  • amino acids: 6
  • half-life: approximately 15-60 minutes; short-acting pulsatile effect
  • type: hexapeptide, ghrelin receptor (GHSR) agonist
  • CAS: 87616-84-0
  • 1980s era of original development (older than GHRP-2)
  • GHSR the ghrelin receptor target
  • massive appetite stimulation magnitude, the defining feature
  • strictly inferior position relative to ipamorelin in 2026

frequently asked questions

What is GHRP-6?

GHRP-6 (Growth Hormone Releasing Peptide-6) is a first-generation synthetic hexapeptide and ghrelin receptor agonist. It is the original GHRP-class compound, predating GHRP-2 and the selective secretagogue ipamorelin.

What does GHRP-6 do?

GHRP-6 stimulates pituitary GH release via the ghrelin receptor. It also produces the strongest appetite-stimulating effect of the GHRP class, plus the cortisol and prolactin elevation shared with GHRP-2. Historically used for bulking phases where increased hunger was considered a useful feature, GHRP-6 has largely been displaced by ipamorelin for everything except the specific appetite-stimulation use case.

How is GHRP-6 typically administered?

The original clinical research used controlled administration, often IV, to study GH, ACTH, cortisol, appetite, and sleep effects. There is no FDA-approved dosing protocol for any human use, and chronic community patterns do not inherit the diagnostic-study safety frame.

What are the side effects of GHRP-6?

Pronounced appetite stimulation (often the defining experience), injection-site reactions, cortisol and prolactin elevation, occasional water retention, and for some users, transient numbness or tingling. The appetite and stress-hormone effects are intrinsic to the pharmacology, though magnitude still depends on exposure and individual response.

Is GHRP-6 FDA approved?

No. GHRP-6 has no FDA approval. It is classified as a research chemical in the US. WADA Prohibited List S2 applies for competitive athletes.

How much does GHRP-6 cost?

No clinical retail price. On the research-chemical market it is priced similarly to GHRP-2 and generally cheaper than ipamorelin.

related peptides

  • ipamorelin — the clean A-tier alternative that obsoleted the whole GHRP class
  • ghrp-2 — the slightly-less-messy first-gen sibling, same tier for same reason
  • cjc-1295 — the GHRH side of GH stimulation, often paired with secretagogues in community use

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.